Tumour Necrosis Factor Inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: combined analysis of European biologics databases by Thomas, Matthew et al.
        
Citation for published version:
Thomas, M, Shaddick, G, Charlton, R, Cavill, C, Holland, R, Iannone, F, Lapadula, G, Lopriore, S, Zavada, J,
Uher, M, Pavelka, K, Szczukova, L, Sidiropolous, P, Flouri, I, Drosos, A, Möller, B, Nissen, M, Müller, R,
Scherer, A, McHugh, N & Nightingale, A 2021, 'Tumour Necrosis Factor Inhibitor monotherapy versus
combination therapy for the treatment of psoriatic arthritis: combined analysis of European biologics databases',












If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. Jun. 2021
 
 
Tumour Necrosis Factor Inhibitor monotherapy versus combination therapy 
for the treatment of psoriatic arthritis: combined analysis of European 
biologics databases 
 
Matthew L. Thomas, Gavin Shaddick, Rachel Charlton, Charlotte Cavill, Richard Holland, 
Florenzo Iannone, Giovanni Lapadula, Simona Lopriore, Jakub Závada, Michal Uher, Karel 
Pavelka, Lenka Szczukova, Prodromos Sidiropolous, Irini Flouri, Alexandros Drosos, Burkhard 
Möller, Michael J Nissen, Rüdiger B Müller, Almut Scherer, Neil McHugh* & Alison 
Nightingale* 
* Joint senior authors 
 
 
Key indexing terms 




Department of Mathematical Science, University of Bath, UK 
Department of Mathematics, University of Exeter, UK 
Department of Pharmacy & Pharmacology, University of Bath, UK 
Royal National Hospital for Rheumatic Diseases, Bath, UK 
Rheumatology Unit – DETO, University of Bari, Italy 
Institute of Rheumatology, Prague, Czech Republic 
Institute of Biostatistics and Analytics, Faculty of Medicine, Masaryk University, Brno, Czech Republic 
Department of Rheumatology, Clinical Immunology, Medical School, University of Crete, Greece 
Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina 
Department of Rheumatology, Immunology & Allergology, Inselspital, University Hospital Bern, 
Switzerland 
Department of Rheumatology, University Hospital Geneva, Switzerland 
Cantonal Hospital, St Gallen, Switzerland 






The study was funded by a non-restricted investigator initiated award from Pfizer. 
 
Conflict of interest 
NM, AN, RC, MT and CC report grants from Pfizer during the conduct of the study. NM 
reports personal fees from AbbVie and Lilly and grants from Lilly outside the submitted 
work. CC reports grants from Celgene, Lilly and Novartis and personal fees from Novartis 
outside of the submitted work. FI reports personal fees from Abbvie, BMS, Novartis, Pfizer, 
Lilly, UCB and MSD outside the submitted work. GL reports personal fees from AbbVie, BMS, 
Novartis, Pfizer and MSD outside the submitted work. KP reports honoraria for 
consultations and speakers fees from AbbVie, Pfizer, UCB, Lilly, Novartis and Roche outside 
the submitted work. PS reports that the Hellenic Registry for Biologic Therapies" was 
supported in part by the Hellenic Rheumatology Society through unrestricted grants from 
Schering-Plough, AbbVie, Pfizer, Bristol Myers Squibb and Roche during the conduct of the 
study. These companies had no role in study design, collection, analysis and interpretation 
of the data and in the writing of the manuscript. PS also reports grants and personal fees 
from the pharma industry through the "University of Crete Special Account for Research", 
outside the submitted work. AD, IF, RH, SL, BM, RM, MN, AS, GS, LS, MU and JZ, have 
nothing to disclose. 
 
Author names, appointments and highest degree 
M Thomas, PhD, Department of Mathematical Science, University of Bath 
G Shaddick, PhD, Department of Mathematics, University of Exeter 
R Charlton, PhD, Department of Pharmacy & Pharmacology, University of Bath 
C Cavill, BSc, Royal National Hospital for Rheumatic Diseases, Bath 
R Holland, MD, Royal National Hospital for Rheumatic Diseases, Bath 
F Iannone, MD, PhD, Rheumatology Unit – DETO, University of Bari 
G Lapadula, MD, Rheumatology Unit – DETO, University of Bari 
S Lopriore, MD, Rheumatology Unit – DETO, University of Bari 
J Závada, MD, PhD, Institute of Rheumatology, Prague, Czech Republic 
M Uher, Institute of Biostatistics and Analytics, Faculty of Medicine, Masaryk University 
K Pavelka, MD, PhD, Institute of Rheumatology, Prague, Czech Republic 
L Szczukova, MD, Institute of Biostatistics and Analytics, Faculty of Medicine, Masaryk University 
 
 18 
P Sidiropolous, MD, PhD, Rheumatology, Clinical Immunology and Allergy Department, Medical 
School, University of Crete 
I Flouri, MD, Rheumatology, Clinical Immunology and Allergy Department, Medical School, 
University of Crete 
A Drosos, MD, PhD, Rheumatology Clinic, Department of Internal Medicine, Medical School, 
University of Ioannina 
B Möller, Prof, Department of Rheumatology, Immunology & Allergology, Inselspital, University 
Hospital Bern  
M J Nissen, MBBS, FRACP, Department of Rheumatology, University Hospital Geneva 
R Müller, MD, Cantonal Hospital, St Gallen 
A Scherer, PhD, SCQM Foundation, Zürich 
N McHugh, MBChB, MD, FRCP, FRCPath, Department of Pharmacy and Pharmacology, University of 
Bath 
A Nightingale, PhD, Department of Pharmacy and Pharmacology, University of Bath 
 
Corresponding Author 
Professor Neil McHugh, Department of Pharmacy & Pharmacology, University of Bath, 
Claverton Down, Bath BA2 7AY, UK.  
Email: n.j.mchugh@bath.ac.uk 
ORCID iD: https://orcid.org/0000-0003-2765-658X 
 
 
Short running head 
TNFi therapy for PsA 
 





To investigate whether tumour necrosis factor inhibitor (TNFi) combination therapy with 
conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is more 
effective for psoriatic arthritis (PsA) and/or improves TNFi drug survival compared to TNFi 
monotherapy. 
Methods  
Five PsA biologics cohorts were investigated between 2000 and 2015; the ATTRA registry 
(Czech Republic), the Swiss Clinical Quality Management PsA registry, the Hellenic Registry 
of Biologics Therapies (Greece), the University of Bari PsA biologics database (Italy) and the 
Bath PsA cohort (UK). Drug persistence was analysed using Kaplan-Meier and equality of 
survival using Log-Rank tests. Comparative effectiveness was investigated using logistic 
regression with propensity scores. Separate analyses were performed on: (a) the combined 
Italian/Swiss cohorts for change in rate of DAS-28; and (b) the combined Italian, Swiss and 
Bath cohorts for change in rate of HAQ.  
Results  
In total, 2294 patients were eligible for the drug survival analysis. In the Swiss (p=0.002), 
Greek (p=0.021) and Bath (p=0.014) databases patients starting TNFi in combination with 
MTX had longer drug survival compared to monotherapy, whilst in Italy the monotherapy 
group persisted longer (p=0.030). In patients from the combined Italian/Swiss dataset 
(n=1066) there was no significant difference between treatment arms in rate of change of 
DAS28. Similarly, when also including the Bath cohort (n=1205) there was no significant 
difference in rate of change of HAQ. 
Conclusion  
Combination therapy of a TNFi with a csDMARD does not appear to affect improvement of 




Tumour necrosis factor inhibitors (TNFi) are an effective treatment for psoriatic arthritis 
(PsA)[1] and are generally prescribed following the failure of initial treatment with 
conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), of which 
methotrexate (MTX) is the most widely used. TNFi may be prescribed as monotherapy or in 
combination with csDMARDs with between 51% and 79% of patients using TNFi in 
combination with MTX.[2] A systematic review of randomised controlled trials (RCTs) and 
observational studies of TNFi monotherapy versus TNFi combination therapy with MTX did 
not find any difference in efficacy for peripheral disease but there was some evidence of 
benefit of combination therapy on TNFi drug survival.[2] Whilst there is clear evidence for the 
benefit of combination TNFi plus csDMARDs in rheumatoid arthritis (RA),[3] the value of 
combination therapy in PsA remains unresolved,[4] and this may explain the variability 
observed in clinical practice, and the lack of clarity in current treatment guidelines. [5, 6] 
 
Biologics registries have been set up globally to investigate the long-term efficacy and safety 
of TNFi. The aim of this study was to combine data from multiple European TNFi databases to 
describe the utilisation patterns of TNFi monotherapy and combination therapy in PsA and 
investigate the comparative effectiveness of TNFi monotherapy versus combination therapy 





Materials and methods  
Participating databases 
An invitation to participate in the study was sent to all European biologics registries known to 
collect data on patients with PsA. Three biologics registries and two hospital-based PsA 
biologics cohorts agreed to participate and were included in the study: The ATTRA registry, 
Czech Republic (the ‘Czech database’); The Swiss Clinical Quality Management (SCQM) in 
Rheumatic Diseases PsA registry, Switzerland (the ‘Swiss Database’); the Hellenic Registry of 
Biologics Therapies (HeRBT), Greece (the ‘Greek Database’); the University of Bari School of 
Medicine PsA biologics database, Italy (the ‘Italian Database’); and the Royal National Hospital 
for Rheumatic Diseases, Bath, UK PsA cohort (the ‘Bath Database’). The hospital-based Italian 
and Bath databases are both prospective cohort studies that have submitted data to the 
Italian GISEA biologics registry and the British Society for Rheumatology rheumatoid arthritis 
biologics registry (BSRBR-RA) respectively and were therefore deemed of sufficiently high 
quality in terms of data collection to be included in the study. Ethics approval was granted for 
each of the five cohorts (for the lead centre this was by the South West-Central Bristol NRES 
Committee – approval number BA74/00-01, all other approvals can be found in 
Supplementary Table 1). A summary of data collection for each database is shown in 
Supplementary Table 2.  
  
Study population 
The study period ran from 01-Jan-2000 to 31-Dec-2015. We included all adults (18 years) 
with a clinical diagnosis of PsA who were new (first line) users of TNFi during the study period, 
and who were registered in their respective biologics database from the time of first TNFi 
prescription. Patients who had been prescribed any other type of biologic DMARD before 
their first TNFi prescription were excluded. Patient and disease characteristics at baseline 
were extracted from the databases.  
 
Drug exposure and patient follow-up  
Recorded prescription data was used to determine exposure status during the follow-up 
period. Exposure to treatment groups was classified at baseline into: TNFi monotherapy, TNFi 
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combination therapy with MTX and this group was also included in a category of TNFi 
combination therapy with any csDMARD (including MTX).  
 
Patient follow-up and outcome measures 
Patients were followed until their censoring date, which was the earliest of (a)the time of 
discontinuation of their first TNFi agent, defined as discontinuation of therapy for at least 
three months; or (b)the date that they were lost to follow-up; or (c)the date of their last 
follow-up on the biologics database whichever was the earliest. Drug persistence was defined 
as the time from TNFi to censoring date.  
 
The primary outcome measure for the comparative effectiveness analyses was rate of change 
of disease activity, measured using the 28-item Disease Activity Score (DAS28),[7] during the 
follow-up period. The secondary outcome measure was rate of change in physical function, 
measured using the Health Assessment Questionnaire (HAQ),[8] during the follow-up period.  
 
Statistical analyses 
Statistical analyses were undertaken using R statistical software.[9] Individual patient data 
from the Bath, Italian and Swiss databases were analysed at the University of Bath, the 
Czech and Greek data were analysed locally. A full description of the statistical methods can 
be found in the Supplementary material. 
 
Drug survival 
Drug survival was analysed using Kaplan-Meier survival estimates and defined as time from 
TNFi initiation to censoring date, stratified by treatment group, age at TNFi initiation and sex.  
The median time from baseline to discontinuation of first TNFi, with 95% confidence intervals 
(CI95), was calculated from the survival function. The equality of the survival functions was 
compared using Log-Rank tests.  
 
Comparative effectiveness 
Due to the complexity of the comparative effectiveness analyses modelling, we only included 
data for which we had individual patient data at the University of Bath (Bath, Italian and Swiss 
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databases). Initial data analysis included examining changes in DAS28 and HAQ over time, 
without adjustment for covariates. 
  
Comparative effectiveness analyses were based on an intention-to-treat analysis approach 
using Negative Binomial regression. Comparisons were made between TNFi monotherapy 
and (a) any TNFi plus csDMARD and, as a sub-group analysis we also compared to (b) 
TNFi+MTX. For HAQ, in order to allow for the observed excess of zeros, a zero-inflated 
Negative Binomial model was used, with a consistent set of covariates used for both 
components of the model. Statistical comparisons were based on the relative difference in 
rates of change in disease score between treatments. 
 
Whilst each registry had planned follow-up periods (for example 3, 6, 12 months), the actual 
dates of follow-up varied substantially around these, with additional follow-up appointments 
also being recorded. Attempting to classify these variable follow-up appointments into 
specific follow-up periods (e.g. change at 3 months, 6 months) resulted in significant loss of 
data. Therefore, we included all follow-up data in the analysis rather than planned time 
points.  
 
The regression models were adjusted for age at TNFi initiation and sex. Differences between 
rates of improvement in the two treatment groups were obtained by including an interaction 
term between time and treatment group in the regression models. To account for any 
confounding by indication, we developed database-specific propensity score models, using 
all available baseline data, to calculate the individual propensity scores for treatment to 
monotherapy or combination therapy. All covariates, that were not explicitly included in the 
model, were included in the propensity score models, including clinical characteristics such 
as disease duration. 
 
Missing values in any explanatory variable (where <70% were missing) were estimated using 
multiple imputation using the Amelia II package in R.[10] In order to test for a significant 
difference in the rate of change for each treatment group, estimates of the log Relative Risk 
(RR) with standard error associated with the interaction between treatment group and time 
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were extracted and then combined to give an overall estimate of RR, together with a 




Results   
There were 2294 eligible patients identified from the contributing databases, of which 34% 
started treatment as monotherapy and 66% as combination therapy. Table 1 summarises 
requirements for access to TNFi and baseline patient characteristics. Clinical guidelines for 
access to TNFi differed across countries. The impact of the guidelines on measures of disease 
severity and activity at TNFi initiation was reflected in the relatively lower HAQ and DAS28 
scores in the Swiss database and higher baseline scores in the Bath database. Comorbidity 
data were not consistently recorded across all of the databases, however, in general the 
proportion of patients with significant comorbidities was <5% of each study population, with 
the exception of a prevalence of latent tuberculosis of 13% in the Italian database due to 
screening for latent TB.  
 
Drug utilisation 
In all centres, TNFi were more commonly prescribed in combination with a csDMARD than as 
monotherapy and MTX was the csDMARD most frequently prescribed (Table 1). Changes in 
baseline prescribing during the study period are shown in Supplemental Figure 1. Patient 
characteristics and baseline disease activity and severity were generally similar across 
treatment groups within the databases (Table 1). Adalimumab and etanercept were the most 
frequently prescribed TNFi in all databases other than the Greek database, where 47.8% of 
patients were treated with Infliximab. Supplemental Table 3 shows the TNFi products 
prescribed at baseline. The majority of patients (81.7% monotherapy and 66.0% combination 
therapy) did not have changes to their baseline treatment regimen before discontinuing their 
first TNFi, and >85% of these changes were made > 12 months after TNFi initiation.  
 
Drug survival 
The Kaplan-Meier survival curves for drug survival on first TNFi, stratified by database and 
baseline treatment regimen, are shown for monotherapy versus any csDMARD combination 
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therapy in Figure 1 and monotherapy versus combination therapy with MTX in Supplemental 
Figure 2.  Figure 2 shows the Kaplan-Meier survival curves for drug survival stratified by sex 
and supplemental Figure 3 shows them stratified by age. Median survival times are shown in 
Table 2. Discontinuation of first TNFi was earliest in patients in the Swiss database (median 
2.8 years, (CI951.5-3.7)); patients in the Greek database had the longest median survival time 
(6.9 years, (CI954.9, NA)).   
 
In all but the Italian database, patients on combination therapy had longer survival on their 
first TNFi than those on monotherapy. This ranged from 0.5 to 2.9 years and the difference 
was statistically significant in the Bath and Swiss databases for any combination and in the 
Bath, Greek and Swiss databases for combination with MTX (Figure 1, Table 2). In the Italian 
database, patients on monotherapy persisted significantly longer on their first TNFi than 
those on combination therapy, but this difference did not remain significant when the 
analyses were limited to combination therapy with MTX. In all but the Czech database, where 
we observed no difference, men persisted significantly longer on their first TNFi than women 
(Figure 3, Table 2).   
 
Comparative effectiveness 
The analysis of rate of change in DAS28 included 1056 patients from the Swiss and Italian 
databases with a DAS28 score recorded; 441 were prescribed TNFi monotherapy at baseline 
and 615 were prescribed combination therapy with any csDMARD, of whom 442 were 
prescribed TNFi+MTX. Sixty-eight patients from the Swiss database were excluded because 
they did not have a DAS28 score recorded. The analysis of rate of change in HAQ included 
1205 patients from the Bath, Swiss and Italian databases (504 monotherapy, 701 combination 
therapy with any csDMARD of whom 505 were exposed to TNFi+MTX). We excluded 107 Swiss 
patients and 11 Bath patients who had no HAQ scores recorded before their censoring dates.  
 
Within the database-specific propensity score models for both the DAS28 and HAQ analyses, 
patients who had previously used csDMARDs had a higher baseline HAQ and those who had 
a history of dactylitis were significantly more likely to be prescribed combination therapy. 
None of the recorded comorbidities were significant in the models and there was no 
difference in the propensity scores for TNFi plus any csDMARD and TNFi-MTX groups. None 
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of the variables included in the Bath propensity score model were significantly associated 
with treatment allocation. 
 
Figures 3 and 4 show the change in DAS28 and HAQ over time, unadjusted for any covariates. 
In both the DAS28 and HAQ analyses, patients on combination therapy had higher baseline 
scores than patients on monotherapy. The pattern of rate of change was similar in both 
analyses with scores dropping sharply in the first year after treatment initiation, increasing 
slightly then stabilising from 12 months onwards. 
 
There was no statistically significant difference in rate of change of DAS28 between patients 
on TNFi monotherapy with those on combination therapy with any csDMARD (combined 
Relative Risk (RRadj) 0.98 (CI95 0.95-1.03)) or on monotherapy compared with TNFi+MTX 
(combined RRadj 0.98 (CI95 0.95-1.02)). There was no statistically significant difference in rate 
of change of HAQ in patients on monotherapy compared to those on combination therapy 
with any csDMARD (combined RRadj 1.02 (CI95 0.98-1.06)) or when compared to those on 
TNFi+MTX (combined RRadj 1.02 (CI95 0.99-1.07)). Inclusion of the propensity scores in the 
models did not significantly change the combined RRs.  
 
There were no notable differences in reasons for stopping first TNFi between the databases. 
Supplementary Table 4 summarises the reasons for treatment discontinuation stratified by 
database and baseline treatment regimen. Overall 23.5% of the 1323 patients from the Bath, 
Italian and Swiss databases discontinued treatment in the first year after TNFi initiation and 
the proportion was lower in patients exposed to TNFi+MTX (21.8%) than those on 
monotherapy (25.9%) or TNFi+non-MTX csDMARD (26.5%). Lack of treatment efficacy was 
the most frequently recorded reason for discontinuation (9.8% overall, 11.3% monotherapy, 
7.9% TNFi+MTX and 10.8% TNFi+non-MTX csDMARD) followed by adverse drug reactions 
(7.6% overall, 7.0% monotherapy, 6.5% TNFi+MTX and 9.4% TNFi+non-MTX csDMARD). Lack 
of treatment efficacy remained the most frequently recorded reason for treatment 




The results of this multi-registry study are consistent with previous studies of TNFi 
monotherapy versus combination therapy treatment in patients with PsA. We found no 
significant difference in clinical outcome between the treatment groups, which is in line with 
observational studies in Sweden,[11] Norway,[12, 13] the UK,[14] Denmark[15] and Finland.[16] A 
recent randomised controlled trial found that combination therapy of etanercept and 
methotrexate may not improve radiographic progression compared with etanercept 
monotherapy, although combination therapy had slightly greater efficacy for dermatologic 
end points.[17] In the Bath, Greek and Swiss databases, patients were found to persist 
significantly longer on their first TNFi when prescribed in combination with MTX than patients 
on TNFi monotherapy.  This has also been observed in studies in Denmark,[15, 18] Norway,[13] 
Sweden[11] and Italy;[19, 20] in Denmark, however, this was only found when adjustments were 
made for other baseline variables.[15] Although some studies have not reported significantly 
longer persistence with MTX,[16, 21, 22] no study has reported longer persistence for patients 
on monotherapy as was observed in the Italian database. One study in the US, however, did 
report different findings for the individual TNFis, with significantly longer persistence for 
etanercept as monotherapy although the opposite was observed for infliximab and there was 
no difference between treatment groups for adalimumab.[22] Our study, however, did not 
look at individual TNFis so could not determine whether the benefit of combination therapy 
varied by TNFi. Our study did find some evidence that a lower proportion of patients on 
TNFi+MTX stop in the first year of treatment due to lack of treatment efficacy or adverse drug 
reactions. The reason for this finding is not clear and whether there is an explanatory 
biological mechanism such as the inhibition of the development of anti-drug antibodies needs 
further investigation.  
 
A study in Sweden had found patients without MTX showed significantly lower drug survival 
due to adverse events but did not find a difference for treatment failure.[11] Our study found 
that, in all but the Czech database, males persist significantly longer on their first TNFi than 
females which has been observed in some studies looking at PsA [15, 19-21, 23-26] but not 
others.[11, 13] This finding has also been reported for RA and ankylosing spondylitis.[27-29] Other 
predictors that have been found to be associated with drug survival include having a higher 
baseline CRP,[11, 15] a low baseline VAS score for global health,[15] being a non-smoker[13] and 
 
 18 
absence of baseline comorbidity,[21, 26, 30] including a metabolic syndrome related co-
morbidity,[31] and obesity.[32] Predictors have also been reported to vary depending on the 
reason for discontinuation, with some being associated with discontinuation for adverse 
events and others for a lack of efficacy.[11, 15]  
 
This study aimed to combine European biologics registry data to investigate treatment 
utilisation patterns and outcomes in PsA. The prescribing criteria and disease activity scores, 
however, were not standardised across databases and as such the drug utilisation analyses 
were carried out separately. For the comparative effectiveness analyses, limitations included 
the fact that individual patient-level data was not available for all databases and also that 
HAQ was the only outcome measure commonly recorded. For the databases where individual 
level data was available and outcome measures were common we have, however, 
demonstrated that statistical models using individual patient data can be developed to 
combine data that has been collected in different healthcare contexts but using similar study 
designs. Although patients from the different databases had differing baseline disease activity 
and severity scores due to differences in access requirements to TNFi across Europe, we have 
demonstrated that clinical outcome measures can be combined by analysing rate of change 
rather than absolute change in DAS28 or HAQ from baseline which was a methodological 
strength of the study.  
 
Another limitation of the data was that the actual dates of follow-up varied considerably. It 
was therefore necessary, when performing the modelling for the comparative effectiveness, 
to include all follow-up data and model time as a continuous covariate, as restricting to 
specific time periods would have resulted in a significant loss of data and the potential for 
bias.  
 
We designed the study to use DAS28 as the primary outcome measure and HAQ as the 
secondary outcome measure because the majority of biologics databases have been set up 
to primarily collect treatment effectiveness and safety data in patients with RA and we 
therefore expected that DAS28 would be the outcome measure more readily available. Whilst 
DAS28 has been validated for use in PsA its usefulness is limited by the exclusion of the ankle 
joints and feet which are frequently affected in PsA. We did, however, find that all databases 
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collected data on HAQ, which is arguably a more relevant outcome measure for studies of 
PsA. However, none of the databases collected data on all of the outcome measures in the 
more disease specific Outcome Measures for Rheumatology (OMERACT) core set of outcomes 
for PsA[33]. As a result, our analysis of the effectiveness of TNFi treatment is limited to physical 
function and cannot take into account other domains important to people with PsA and to 
cost-effectiveness analyses such as pain, fatigue, work productivity, enthesitis or skin disease 
activity and health related quality of life.  
 
We used propensity score modelling to attempt to minimise the impact of confounding by 
indication and channelling bias, however the effectiveness of propensity score adjustment for 
treatment allocation is limited by the variables collected in the databases and whether they 
are the variables that might be associated with treatment allocation. We used all available 
data within the propensity score models and both a history of dactylitis and higher baseline 
HAQ scores predicted the use of combination treatment. However, there were issues with 
large amounts of missing data for some variables and we had no measures of previous 
treatment compliance, tolerance or success. Therefore, we cannot rule out the potential for 
uncontrolled confounding by indication and it is not possible to predict the impact that this 
might have on the findings of the study.   
 
In conclusion, we have demonstrated the feasibility of combining biologics registry and 
database data to investigate the comparative effectiveness of TNFi treatment for PsA but as 
with all observational studies the results need to be interpreted with caution. We have found 
that whilst there is no significant difference in treatment outcome, as measured using DAS28 
and HAQ, patients on combination therapy persist longer on their first TNFi than those on 
monotherapy. Gender appears to be a major risk factor in determining TNFi survival, with 
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Table 1.  Patient characteristics stratified by biologics database and baseline treatment regimen 
Baseline 
characteristic 
ATTRA – Czech Republic Bari – Italy Bath – UK HeRBT – Greece SCQM - Switzerland 
No of patients 658 (358 males, 300 females) 300 (140 males, 160 females) 199 (100 males, 99 females) 314 (142 males, 172 females) 824 (407 males, 417 females) 
Criteria for PsA Moll & Wright to 2012  
Moll & Wright or CASPAR from 
2012 
CASPAR CASPAR Clinical diagnosis by a 
rheumatologist (usually using 
CASPAR) 




PsA not adequately controlled 
using csDMARDs 
EULAR guidelines: Inadequate 
response to 1 csDMARD 
EULAR / BSR guidelines: 
peripheral arthritis with 3 SJC 
and 3TJC and inadequate 
response to 2 csDMARDs 
HSR guidelines: peripheral 
arthritis with 3 SJC and 3TJC 
and inadequate response to 2 
csDMARDs or BASDAI >4 and 
inadequate response 2 NSAIDs 
No rigid guidelines but generally 
active disease with inadequate 




























































Males (%) 48.2 52.2 50.1 51.8 43.8 43.2 46.5 53.1 49.3 61 52.7 53.4 52.3 47.1 48.4 









































































































22.0 29.4 30.0 80.0 75.3 78.8 72.1 82.3 80.0 9.1 10.1 10.8 28.7 29.1 28.1 
Smoking unknown (%) 73.8 64.6 64.2 0.0 0.0 0.0 13.9 4.4 5.3 74.0 82.7 81.4 61.2 60.5 63.1 
BMI <25 (%) 19.1 22.4 20.7 29.1 32.1 32.1 9.3 19.5 14.6 
24.7 14.3 14.2 
33.3 29.5 27.8 
BMI 25-29 (%) 19.9 29.0 28.1 38.2 41.6 41.8 37.2 37.2 42.7 28.7 30.2 31.9 
BMI 30 (%) 14.2 20.5 20.9 30.9 24.7 24.6 40.7 39.8 38.6 6.5 11.4 13.2 18.2 19.1 19.1 




























































Data in grey italic text indicates that >50% of the data values were missing. IQR, interquartile range; csDMARD, conventional synthetic anti-rheumatic drug – note that the category ‘any csDMARD’ includes patient 
prescribed combination therapy with MTX;  EULAR, European League Against Rheumatism TNFi guidelines; BSR, British Society for Rheumatology TNFi guidelines; HSR, Hellenic Society for Rheumatology guidelines; 
TJC, tender joint count; SJC, swollen joint count; BASDAI, Bath Ankylosing Spondylitis Activity Index; NSAID, non-steroidal anti-inflammatory drug; Mono, monotherapy; CASPAR, Classification of psoriatic arthritis; 




Table 2. Median survival times from TNFi initiation to discontinuation of first TNFi stratified by baseline treatment regimen and database 
 
 ATTRA- Czech Republic Bari - Italy Bath - UK HeBRT - Greece SCQM - Switzerland 
 n Median survival 
time (years) (CI95) 
n Median survival 
time (years) (CI95) 
n Median survival 
time (years) (CI95) 
n Median survival 
time (years) (CI95) 
n Median survival 
time (years) (CI95) 
All 658 5.9 (4.7, 7.6) 300 4.9 (4.1, 6.6) 199 4.8 (3.6, 6.6) 314 6.9 (4.9, NA) 824 2.8 (2.5, 3.7) 
Treatment regimen at baseline (combination therapy with any csDMARD including MTX) 
Monotherapy 141 4.8 (3.8, NA) 110 6.9 (4.7, NA) 86 3.2 (1.3, 6.5) 77 4.3 (2.9, 8.3) 363 2.6 (1.7, 3.3) 
Combination therapy 517 5.9 (4.7, 7.3) 190 4.3 (3.2, 6.2) 113 6.1 (4.5, NA) 237 7.2 (5.3, NA) 461 3.1 (2.6, 4.7) 
p-value*  0.6054  0.0303  0.0105  0.0609  0.0288 
Treatment regimen at baseline (combination therapy with MTX) 
Monotherapy 141 4.8 (3.5, NA) 110 6.9 (4.7, NA) 86 3.2 (1.3, 6.5) 77 4.3 (2.9, 8.3) 363 2.6 (1.7, 3.3) 
Combination therapy  363 6.3 (4.5, 8.0) 146 4.9 (3.9, 6.6) 75 6.1 (4.5, NA) 204 NA (5.4, NA) 320 4.3 (3.0, 6.3) 
p-value*  0.5550  0.0737  0.0135  0.0208  0.0020 
Age 
18-49 years 370 6.6 (4.3, 8.9) 157 6.0 (4.1, 8.2) 99  5.1 (3.6, NA) 157 7.2 (4.9, NA) 447 3.8 (2.8, 4.6) 
50 years and over 288 5.4 (4.4, 7.6) 143 4.5 (3.4, 6.2) 100 4.8 (3.2, NA) 157 6.9 (4.3, NA) 377 2.2 (1.6, 2.9) 
p-value*  0.9958  0.3319  0.7923  0.9289  0.0089 
Sex 
Female 320 5.7 (4.2, 8.2) 160 3.8 (2.7, 4.9) 99 2.4 (1.6, 6.1) 142 4.3 (2.8, 7.8) 417 2.0 (1.5, 2.7) 
Male 338 5.9 (4.6, 8.9) 140 7.0 (5.5, 10.7) 100 6.6 (4.8, NA) 172 NA (5.9, NA) 407 4.2 (3.2, 5.6) 
p-value*  0.6075  0.0036  0.0100  0.0035  <0.0001 









Figure 1. Kaplan-Meier survival estimates from TNFi initiation to discontinuation of first TNFi or data censoring stratified by baseline 
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Figure 3. DAS28 over time, unadjusted for any covariates, among patients from the Italian and Swiss databases from TNFi initiation to the 
earliest of:  discontinuation of first TNFi; or date of data censoring; or 60 months follow-up for (3a) monotherapy versus combination TNFi 



















































Figure 4. HAQ over time, unadjusted for any covariates, among patients from the Bath, Italian and Swiss databases from TNFi initiation to 
the earliest of: discontinuation of first TNFi; or date of data censoring; or 60 months follow-up for (4a) monotherapy versus combination 







































Supplementary material – statistical analysis 
 
Comparative effectiveness analyses 
Due to the complexity of the comparative effectiveness analyses modelling, we only included data for which 
we had individual patient data at the University of Bath (Bath, Italian and Swiss databases). The availability 
of patient characteristic and outcome data varied between databases and local clinical practice also varied. 
Initial data analysis included examining changes in DAS28 and HAQ over time, without adjustment for 
covariates, using non-parametric (loess) smoothers. 
  
Comparative effectiveness analyses were based on an intention-to-treat analysis approach. Patients were 
followed until their censoring date, which was the earliest of (a) the time of discontinuation of their first 
TNFi agent, defined as discontinuation of therapy for at least three months; or (b) the date that they were 
lost to follow-up; or (c) the date of their last follow-up on the biologics database whichever was the earliest. 
Whilst the formulation of the HAQ and DAS28 means that they are continuous scores, in practice the manner 
in which they are measured (and rounded), results are typically more categorical in nature (e.g. 84% of the 
data was grouped in multiples of 0.125). Based on the discretisation observed in the data, HAQ scores were 
categorised into groups with a width of 0.25 and DAS28 scores into groups with a width of 1. For HAQ, in 
order to allow for the observed excess of zeros, a zero-inflation model was used with two components. These 
components represent the two mechanisms through which zeros can be generated (i) a binomial distribution 
(with a specified probability of generating a zero); and (ii) distribution that represents the observed data 
(that can also generate zeros). As examination of the outcome showed clear indication that the data were 
highly skewed and discontinuous, the latter distribution was chosen to be Poisson with allowance for over-
dispersion through the use of the Negative Binomial. A consistent set of covariates were used for both 
components of the model. For DAS28, an excess of zeros was not observed and the Negative Binomial was 
used. These regression models were used to a compare TNFI monotherapy to (a) any TNFi plus csDMARD 
and, as a sub-group analysis we also compared to (b) TNFi+MTX, with comparisons based on the relative 
difference in rates of change in disease score between treatments. 
 
Whilst each registry had planned follow-up periods (for example 3 months, 6 months, 12 months), the actual 
dates of follow-up varied substantially around these dates with additional follow-up appointments being 
recorded in the databases. Attempting to classify these variable follow-up appointment dates into specific 
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follow-up periods (e.g. change at 3 months, change at 6 months) resulted in significant loss of data. 
Therefore, we included all follow-up data in the analysis using the actual follow-up dates rather than planned 
time points.  
 
Regression models were adjusted for age at TNFi initiation and sex. Differences between rates of 
improvement in the two treatment groups were obtained by including an interaction term between time 
and treatment group in the regression models. Whilst we made the assumption that the clinical populations 
were sufficiently similar in terms of the certainty of diagnosis that their data could be combined, we included 
indicator variables for each database to account for any potential heterogeneity in the DAS28 and HAQ 
scores observed between databases.  
 
Clinically, we might expect there to be inherent differences between patients prescribed monotherapy or 
combination therapy (confounding by indication). If present, these differences would likely result in biased 
estimates of treatment effectiveness. To account for any confounding by indication observed, we developed 
database-specific propensity score models, using all available baseline covariate data, to calculate the 
individual propensity scores for treatment to monotherapy or combination therapy. The cohort-specific 
propensity score models were then included in the overall pooled model. Using propensity score matching 
would have resulted in a significant loss of data therefore we included the propensity scores as continuous 
covariates in the models. The table below shows the variables that were used in each of the propensity score 
models. 
 
Missing values in any explanatory variable were estimated using multiple imputation using the Amelia II 
package in R. Variables were removed from the imputation model if they had more than 70% missing values 
(this only applied to the Baseline Patient Visual Analogue Score in the Bath dataset). The regression and 
propensity score models were run repeatedly for each imputed dataset. In order to test for a significant 
difference in the rate of change for each treatment group, estimates of the log Relative Risk (RR) with 
standard error associated with the interaction between treatment group and time were extracted and then 




Variables included in the propensity score models 
 
Variable description Italy Switzerland Bath 
BMI at baseline  ✔ ✔ ✔ 
Comorbidities - Psoriasis ✔ ✔ ✔ 
Comorbidities - Cardiac Failure ✔ ✔ ✘ 
Comorbidities - Malignant Tumour ✔ ✔ ✘ 
Comorbidities - Lymphoma ✘1 ✘1 ✘ 
Comorbidities - COPD ✔ ✔ ✘ 
Comorbidities - Pulmonary disease ✔ ✔ ✘ 
Comorbidities - Chronic hepatopathy ✔ ✔ ✘ 
Comorbidities - Tuberculosis ✔ ✔ ✘ 
Comorbidities - Inflammatory bowel disease ✔ ✘ ✘ 
Comorbidities - Uveitis ✔ ✔ ✘ 
Comorbidities - Alcohol Abuse ✘1 ✔ ✘ 
Comorbidities - Arterial Hypertension ✔ ✔ ✘ 
Disease duration at baseline ✔ ✔ ✔ 
Previously taken Methotrexate (MTX) ✔ ✔ ✔ 
Previously taken DMARDs ✔ ✔ ✔ 
Number of previous DMARDs (including MTX) ✔ ✔ ✔ 
Name of baseline TNFi ✔ ✔ ✔ 
Axial spondyloarthropathy at baseline ✔ ✔ ✘ 
Peripheral arthritis at baseline ✔ ✔ ✘ 
Enthesitis at baseline ✔ ✔ ✘ 
Dactylitis at baseline ✔ ✔ ✘ 
Baseline 66 Swollen Joint Count score ✔ ✔ ✔ 
Baseline 68 Tender Joint Count score ✔ ✔ ✔ 
Baseline Disease Activity Score 284 ✔ ✔ ✘ 
Baseline Physician Visual Analogue Score ✔ ✔3 ✔ 
Baseline Patient Visual Analogue Score ✔ ✔3 ✘2 
Baseline Pain Visual Analogue Score ✔ ✔3 ✔ 
Baseline Health Assessment Questionnaire Score4 ✔ ✔ ✔ 
Baseline Erythrocyte Sedimentation Rate ✔ ✔ ✘ 
Baseline C-Reactive Protein  ✔ ✔ ✘ 
Baseline EQ5D Score ✘ ✔ ✔ 
Baseline Erosions  ✘ ✘ ✔ 
Hospital Type - Office or Hospital ✘ ✔ ✘ 
1 The data was collected but there were no cases 
2 Not included as >70% of the data were missing  
3 Not a VAS but a numerical rating scale 







Supplemental Figure 1: Baseline treatment regimen stratified by database and year of TNFi initiation with combination therapy separated 





Supplemental Figure 2. Kaplan-Meier survival estimates from TNFi initiation to discontinuation of first TNFi or data censoring stratified by 
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